Loading
Pembrolizumab produced responses in about 45 percent of patients with primary mediastinal B-cell lymphoma that had relapsed after chemotherapy, a lymphoma whose frequent 9p24.1 amplification makes it unusually sensitive to PD-1 blockade.
Phase 2 study of 53 patients with relapsed or refractory primary mediastinal large B-cell lymphoma treated with pembrolizumab, supported by a phase 1b cohort of 21 patients.
Objective response was 45 percent with complete responses in 13 percent, median duration of response not reached after a median follow-up of 12.5 months, and no deaths from treatment-related events; 9p24.1 alterations were near-universal.
Pembrolizumab is approved for relapsed primary mediastinal B-cell lymphoma and is the usual bridge to CAR-T or transplant in chemotherapy-refractory patients.
Shares Primary mediastinal (thymic) large B-cell lymphoma, Journal of Clinical Oncology.
Shares Primary mediastinal (thymic) large B-cell lymphoma, Pembrolizumab.